Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices

Professional Development

Integrative Harm Reduction Psychotherapy & Psychedelic-Assisted Therapy for Problematic Substance Use & Other Addictive Behaviors: A Three Day Clinical Training

Two empty chairs face each other in a softly lit consultation room, with a blank notebook on a small side table.

Integrative Harm Reduction Psychotherapy & Psychedelic-Assisted Therapy for Problematic Substance Use & Other Addictive Behaviors: A Three Day Clinical Training is a three-day professional development intensive led by Andrew Tatarsky, PhD & Casey Paleos, MD, December 11–13, 2026, at InnerMost in Gramercy, New York, NY, US. Co-hosted by InnerMost, Journey Clinical, and MAPS, the training explores the question of compassionate curiosity about why someone uses substances, rather than abstinence, as an entry point into psychedelic-assisted therapy. Listed on the MAPS events calendar with two sessions, the first listed for December 11, 2026, at 4:30 PM; the source also says “This November,” which conflicts with the supplied December dates.

Hosted with: Psychedelic Writers Guild